Sigrid Therapeutics is dedicated to revolutionizing obesity and diabetes management through its innovative SiPore® technology. Here are details of Sigrid‘s latest funding round :

🚀 Launch
2014
🏭 Industry
Biotechnology
🧠Management
Sana Alajmovic (Co-Founder & CEO)
💸 Funding & Investors
INVESTMENT (October 2023) | $4 million |
INVESTORS (October 2023) |
🎯 Funding purpose
The funds will be instrumental in accelerating the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health.
🌐 Country HQ
Sweden (Stockholm)